|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
V600E) and the subsequent development of specific BRAF inhibitors have greatly improved the treatment of metastatic melanoma.
|
23413975 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 75-year-old male developed a swelling in his left inguinal region and was diagnosed with a metastatic melanoma, which was found to harbor a BRAF V600E mutation.
|
31260118 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 75-year-old woman was diagnosed with a BRAF V600E mutated metastatic melanoma.
|
25185693 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A combination of dabrafenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations.
|
25265492 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.
|
24178368 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma.
|
27336602 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A vemurafenib-resistant human metastatic melanoma cell line positive for the BRAF V600E mutation was established.
|
27354627 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although cAMP elevation did not alter the sensitivity of metastatic melanoma cells to BRAF(V600E) and MEK inhibitors, the EPAC-RAP1 axis appears to contribute to resistance to MAPK pathway inhibition.
|
28851815 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although vemurafenib has been shown to improve the overall survival of patients with metastatic melanoma harboring the BRAF V600E mutation, its efficacy is often hampered by drug resistance acquired within a relatively short period through several distinct mechanisms.
|
30920401 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
As the detection of the BRAF V600E mutation has a direct impact on treatment decision, an accurate screening for BRAF mutations in patients with advanced or metastatic melanoma is mandatory.
|
26020488 |
2015 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Assessment of BRAF p.V600E mutational status has become necessary for treatment of patients with metastatic melanoma.
|
23651150 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
B-RAF inhibitors (BRAFi) have been shown to improve rates of overall and progression-free survival in patients with stage IV metastatic melanoma positive for the BRAF V600E mutation.
|
22726224 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
B-Raf(V600E) inhibitors are an important anticancer drug class for metastatic melanoma therapy.
|
24901049 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF kinase inhibitors have dramatically affected treatment of BRAF(V600E) (/) (K)-driven metastatic melanoma.
|
25948295 |
2015 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.
|
23403819 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
|
27151331 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF/MEK inhibition is a standard of care for patients with <i>BRAF</i> V600E/K-mutated metastatic melanoma.
|
31580757 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
|
22646765 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Control of BRAF(V600E) metastatic melanoma by BRAF inhibitor (BRAF-I) is limited by intrinsic and acquired resistance.
|
24732172 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Currently, several targeted therapy regimens are approved as first-line treatment in V600E/K-mutant advanced and metastatic melanoma.
|
31305324 |
2020 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
|
26109403 |
2015 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
|
23051966 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dabrafenib is an inhibitor of BRAF V600E used for treating metastatic melanoma but a majority of patients experience adverse effects.
|
28429064 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dabrafenib plus trametinib significantly prolonged progression-free survival (PFS) and overall survival (OS), improved objective response rates (ORRs) and preserved health-related quality of life (HR-QOL) to a greater extent than dabrafenib (in the double-blind COMBI-d study) and vemurafenib (in the open-label COMBI-v study) in two large, randomized, phase III studies in treatment-naïve patients with unresectable or metastatic melanoma with BRAF (V600E/K) mutation.
|
27246822 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dabrafenib, a novel selective small-molecule inhibitor of BRAF, has been shown to increase overall survival in patients with unresectable metastatic melanoma harboring the BRAF V600E mutation.
|
27624900 |
2017 |